Baseline Characteristics from Evoke and Evoke+ : Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)
OBJECTIVE: We report the preliminary baseline characteristics in the ongoing phase 3 evoke and evoke+ trials investigating the safety and efficacy of oral semaglutide for early AD.BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is approved for use in type 2 diabetes (T2D) or obesity.DESIGN/METHODS: evoke (NCT04777396) and evoke+ (NCT04777409) are multicenter, randomi